« Zurück
Startseite /
Vincristine (sulfate)

Vincristine (sulfate)

ArtNr	HY-N0488-5mg
Hersteller	MedChem Express
CAS-Nr.	2068-78-2
Menge	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.81
Citations	[1]Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.\|[2]Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87.\|[3]Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7.\|[4]Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000.\|[5]Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7.\|[6]Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Acta Pharmacol Sin. 2024 Jun 6.\|Am J Cancer Res. 2021 Apr 15;11(4):1428-1445.\|bioRxiv. 2023 Jul 25.\|bioRxiv. 2023 Jun 3.\|bioRxiv. 2023 Sep 16.\|bioRxiv. 2024 July 04.\|Br J Cancer. 2024 Aug 22.\|Cancer Commun (Lond). 2024 Apr;44(4):469-490.\|Cancer Immunol Res. 2023 May 3;11(5):583-599.\|Cancers (Basel). 2021, 13(13), 3323.\|Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8.\|Cell Commun Signal. 2024 Jun 13;22(1):325.\|Cell Death Dis. 2025 Mar 12;16(1):170.\|Cell Rep Med. 2024 Mar 19;5(3):101468.\|Cell. 2024 Apr 25;187(9):2288-2304.e27.\|Drug Des Devel Ther. 2025 Feb 7:19:827-840.\|Eur J Med Chem. 2018 Feb 25;146:157-170.\|Front Microbiol. 2019 May 9;10:939. \|Front Oncol. 2021 Apr 22;11:665763.\|Front Oncol. 2021 Apr 6.\|Front Oncol. 2024 Jul 19:14:1440650.\|Hum Exp Toxicol. 2021 Feb 4;960327121991901.\|Int J Biol Macromol. 2019 Jan 30;128:574-582.\|Int J Nanomedicine. 2017 Mar 16;12:2081-2108.\|J Chromatogr B. 2021, 122591.\|J Clin Invest. 2024 Mar 7:e172716.\|Leuk Lymphoma. 2020 Feb;61(2):420-428.\|Leukemia. 2021 Mar 29.\|Mol Cancer. 2024 Jan 10;23(1):12.\|Mol Ther. 2021 Jul 1;S1525-0016(21)00353-1.\|Neurobiol Learn Mem. 2019 Sep;163:107038.\|Oncotarget. 2017 Dec 2;8(68):112313-112329.\|Pharmacol Res. 2024 May 9:204:107208.\|PLoS Biol. 2024 June 27.\|Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2208457119.\|Sci Adv. 2023 Feb 10;9(6):eade9238.\|Sci Rep. 2019 Aug 12;9(1):11677.\|SLAS Discov. 2024 Feb 12;29(2):100147.\|Biochem Biophys Res Commun. 2023 Jun 27;674:27-35.\|Biomed Pharmacother. 2020 May;125:110003.\|bioRxiv. 2023 Apr 14.\|bioRxiv. 2023 Feb 27.\|bioRxiv. 2019 Dec.\|Breast Cancer Res Treat. 2023 May 19.\|Cancers (Basel). 2022 Oct 19;14(20):5127.\|Cell Mol Immunol. 2023 Jan;20(1):51-64.\|DRUG RESIST UPDATE. 2023 Feb 13;68:100951.\|Front Oncol. 2020 Mar 13;10:308.\|Front Pharmacol. 15 July 2022.\|J Biomed Inform. 2023 May 15;104383.\|J Transl Med. 2023 Jan 9;21(1):9.\|Mol Pharm. 2022 Oct 21.
Smiles	CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Leurocristine (sulfate),NSC-67574 (sulfate),22-Oxovincaleukoblastine (sulfate)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Microtubule/Tubulin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	923.04
Product Description	Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 83.33 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-N0488-5mg-safety-datasheet.pdf